These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2702992)

  • 21. [Phase II study of 5'-DFUR (Furtulon) capsule for bladder cancer].
    Kubota Y; Miura T; Shuin T; Kinoshita Y; Hosaka M; Kondo I; Moriyama M; Fukushima S; Fukuoka H; Miyai K
    Gan To Kagaku Ryoho; 1991 Oct; 18(13):2301-6. PubMed ID: 1834023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy of metastatic bladder cancer.
    Yagoda A
    Cancer; 1980 Apr; 45(7 Suppl):1879-88. PubMed ID: 7189443
    [No Abstract]   [Full Text] [Related]  

  • 23. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients.
    Salzberg M; Borner M; Bauer JA; Morant R; Rauch D; Rochlitz C
    Eur J Cancer; 2006 Oct; 42(15):2660-1. PubMed ID: 16934972
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
    Panduro J; Hansen M; Hansen HH
    Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of tryptophan mustard (NSC-62403) in patients with plasmacytic myeloma.
    Kyle RA; Carbone PP; Lynch JJ; Owens AH; Costa G; Silver RT; Cuttner J; Harley JB; Leone LA; Shnider BI; Holland JF
    Cancer Res; 1967 Mar; 27(3):510-5. PubMed ID: 5336511
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate.
    Seligman PA; Crawford ED
    J Natl Cancer Inst; 1991 Nov; 83(21):1582-4. PubMed ID: 1960756
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase II trial of neocarzinostatin in patients with bladder and prostatic cancer: toxicity of a five-day iv bolus schedule.
    Natale RB; Yagoda A; Watson RC; Stover DE
    Cancer; 1980 Jun; 45(11):2836-42. PubMed ID: 6445776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase-II study of neoadjuvant chemotherapy in T3-4N0-XM0 transitional cell carcinoma of the bladder: a preliminary analysis.
    Splinter TA; Schröder FH; Denis L; Newling D; Jacqmin D; Hall RR; de Pauw M
    Eur Urol; 1988; 14 Suppl 1():24-6. PubMed ID: 3181236
    [No Abstract]   [Full Text] [Related]  

  • 29. [1st experiences in the treatment of ovarian tumors with Peptichemio].
    Natale N; Mangioni C; Remotti G
    Minerva Med; 1974 May; 65(33):1805-10. PubMed ID: 4367233
    [No Abstract]   [Full Text] [Related]  

  • 30. Porfiromycin in the management of epidermoid and transitional cell cancer: a phase II study.
    Panettiere FJ; Talley RW; Torres J; Lane M
    Cancer Treat Rep; 1976 Jul; 60(7):907-11. PubMed ID: 795539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma--response rate and pitfalls. MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party).
    Fosså SD; Harland SJ; Kaye SB; Raghavan D; Russell JM; Parmar MK; Uscinska BM; Wood R
    Br J Urol; 1992 Aug; 70(2):161-8. PubMed ID: 1393439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors.
    Higby DJ; Wallace HJ; Albert DJ; Holland JF
    Cancer; 1974 May; 33(5):1219-5. PubMed ID: 4856724
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase II study with a new alkylating agent (PTT-119) in lymphoid malignancies.
    Tura S; Mazza P; Gherlinzoni F; Zinzani PL; Poletti G; Visani G; Lemoli RM; Bandini G; Cavo M; Galieni P
    Haematologica; 1988; 73(6):503-8. PubMed ID: 3148513
    [No Abstract]   [Full Text] [Related]  

  • 34. Intravesical chemoprophylaxis of superficial transitional cell carcinoma of the bladder. When should the drug be given?
    Bouffioux C
    Prog Clin Biol Res; 1985; 185B():47-55. PubMed ID: 4034591
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study.
    Al-Sarraf M; Frank J; Smith JA; O'Bryan RM; Costanzi JJ; Stephens RL; Caraveo J; Crawford ED
    Cancer Treat Rep; 1985 Feb; 69(2):189-94. PubMed ID: 2578880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II studies of mitozolomide in melanoma, lung and ovarian cancer.
    Harding M; Docherty V; Mackie R; Dorward A; Kaye S
    Eur J Cancer Clin Oncol; 1989 May; 25(5):785-8. PubMed ID: 2544429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of aniline mustard in patients with multiple myeloma.
    Kyle RA; Costa G; Cooper MR; Ogawa M; Silver RT; Glidewell O; Holland JF
    Cancer Res; 1973 May; 33(5):956-60. PubMed ID: 4703127
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU.
    Young RC; DeVita VT; Serpick AA; Canellos GP
    N Engl J Med; 1971 Aug; 285(9):475-9. PubMed ID: 5558887
    [No Abstract]   [Full Text] [Related]  

  • 39. [Results of 18 months of chemotherapy with Peptichemio].
    Battelli T; Bonsignori M; Manocchi P; Perilli A
    Minerva Med; 1974 Sep; 65(62):3235-43. PubMed ID: 4609310
    [No Abstract]   [Full Text] [Related]  

  • 40. Chemotherapy for bladder cancer with neocarzinostatin: evaluation of systemic administration.
    Sakamoto S; Ogata J; Ikegami K; Maeda H
    Eur J Cancer (1965); 1980 Jan; 16(1):103-13. PubMed ID: 6444585
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.